ReviewPharmaceuticals (Basel, Switzerland)2025
Combating Antimicrobial Resistance: Innovative Strategies Using Peptides, Nanotechnology, Phages,
Review in Pharmaceuticals (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- Molecular and environmental drivers of antimicrobial resistance: global epidemiology, resistome dynamics, and one health strategies.Archives of microbiology · 2026Review
- Review
- Dual-Mode Native Mass Spectrometry Screening Identifies Ginsenoside Ligands of 6-Hydroxymethyl-7,8-Dihydropterin Pyrophosphokinase (HPPK).Molecules (Basel, Switzerland) · 2026Article
- Role of antimicrobial peptide-based biomaterials in respiratory tract infections control.BMC microbiology · 2026Review
- Bacterial Persister Cells as Evolutionary Catalysts of Antibiotic Resistance: Mechanisms, Clinical Implications, and Therapeutic Strategies.Antibiotics (Basel, Switzerland) · 2026Review
- Antibacterial and antibiofilm activity of a triterpenoid-rich Eucalyptus globulus leaf extract against gram-positive bacteria.Scientific reports · 2026Article
- Targeting Bacterial Infections in Periodontal Disease: From Conventional Antibiotics to Next-Generation Therapeutics.Antibiotics (Basel, Switzerland) · 2026Review
- Green mycosynthesis of a CuO/ZnO heterojunction nanocomposite using Aspergillus terreus and its antibacterial and anti-virulence activity against multidrug-resistant Escherichia coli.Scientific reports · 2026Article
- Antimicrobial Consumption and Resistance Dynamics Across Healthcare Level: Global Evidence and Stewardship Implications.Pathogens (Basel, Switzerland) · 2026Review
- A review of phytochemicals targeting bacterial biofilm and quorum sensing pathways: molecular, microbiological, and mechanistic insights.Archives of microbiology · 2026Review
- ERS Congress 2025: highlights from the Respiratory Infections Assembly.ERJ open research · 2026Article
- Editorial: New Strategies to Combat Antimicrobial Resistance in Infectious Diseases.Pharmaceuticals (Basel, Switzerland) · 2026Article
- The role of bacteriophages and CRISPR-Cas in combating multidrug-resistant bacteria.Natural products and bioprospecting · 2026Review
- Next-Generation Strategies for Controlling Foodborne Pathogens: Precision Antimicrobials, Biofilm Disruption, and Emerging Molecular Interventions.Foods (Basel, Switzerland) · 2026Review
- Artificial intelligence in optimizing antimicrobial therapy for gastro-renal disorders.Frontiers in cellular and infection microbiology · 2026Review
- New potential antimicrobial peptides with mirror-symmetrical structure in fungi and insects.Frontiers in microbiology · 2026Article
- Editorial: Integrative microbial and chemical genomics to decipher antibiotic resistance mechanisms and developing innovative antimicrobial approaches.Frontiers in microbiology · 2026Article
- Nano-enabled disruption of bacterial virulence and communication in plant pathosystems: emerging strategies for sustainable disease management.Frontiers in plant science · 2026Review
- Biofilm Formation on Indwelling Medical Devices: A Review of Health and Economic Implications.International journal of microbiology · 2026Review
- Translating microbial knowledge into clinical biofilm therapies.Open medicine (Warsaw, Poland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Antimicrobial resistance (AMR) has emerged as one of the most pressing global health challenges of our time. Alarming projections of increasing mortality from resistant infections highlight the urgent need for innovative solutions. While many candidates have shown promise in preliminary studies, they often encounter challenges in terms of efficacy and safety during clinical translation. This review examines cutting-edge approaches to combat AMR, with a focus on engineered antimicrobial peptides, functionalized nanoparticles, and advanced genomic therapies, including Clustered Regularly Interspaced Short Palindromic Repeats-associated proteins (CRISPR-Cas systems) and phage therapy. Recent advancements in these fields are critically analyzed, with a focus on their mechanisms of action, therapeutic potential, and current limitations. Emphasis is given to strategies targeting biofilm disruption and quorum sensing interference, which address key mechanisms of resistance. By synthesizing current knowledge, this work provides researchers with a comprehensive framework for developing next-generation antimicrobials, highlighting the most promising approaches for overcoming AMR through rational drug design and targeted therapies. Ultimately, this review aims to bridge the gap between experimental innovation and clinical application, providing valuable insights for developing effective and resistance-proof antimicrobial agents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.